Atyr Pharma Files 10-Q for Q2 2024

TL;DR

Atyr Pharma dropped its Q2 10-Q. Check financials and biz updates.

AI Summary

Atyr Pharma Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business operations. Key financial figures and operational highlights are detailed within the filing.

Why It Matters

This filing provides investors with a quarterly update on Atyr Pharma's financial health and strategic progress, crucial for understanding the company's trajectory in the biopharmaceutical sector.

Risk Assessment

Risk Level: medium — As a biopharmaceutical company, Atyr Pharma faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

• 1231 — Fiscal Year End (Indicates the end of the company's annual accounting period.)

Key Players & Entities

• aTYR PHARMA INC (company) — Filer
• 20240630 (date) — Period of Report
• 20240813 (date) — Filing Date
• SAN DIEGO (location) — Business Address City

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share ATYR The Nasdaq Capital M

Filing Documents

• atyr-20240630.htm (10-Q) — 1724KB
• atyr-ex31_1.htm (EX-31.1) — 11KB
• atyr-ex31_2.htm (EX-31.2) — 11KB
• atyr-ex32_1.htm (EX-32.1) — 8KB
• atyr-ex32_2.htm (EX-32.2) — 7KB
• 0000950170-24-096185.txt ( ) — 6589KB
• atyr-20240630.xsd (EX-101.SCH) — 1072KB
• atyr-20240630_htm.xml (XML) — 982KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements 3 Condensed Consolidated Balance Sheets as of June 30, 2024 (unaudited) and December 31, 2023 3 Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2024 and 2023 (unaudited) 4 Condensed Consolidated Statements of Comprehensive Loss for the three and six months ended June 30, 2024 and 2023 (unaudited) 5 Condensed Consolidated Statements of Stockholders' Equity for the three and six months ended June 30, 2024 and 2023 (unaudited) 6 Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2024 and 2023 (unaudited) 7 Notes to Condensed Consolidated Financial Statements (unaudited) 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 16

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 23

Controls and Procedures

Item 4. Controls and Procedures 23

OTHER INFORMATION

PART II. OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 24

Risk Factors

Item 1A. Risk Factors 24

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 60

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 60

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 60

Other Information

Item 5. Other Information 60

Exhibits

Item 6. Exhibits 61

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements aTyr Pharma, Inc. Condensed Consolida ted Balance Sheets (in thousands, except share and per share data) June 30, December 31, 2024 2023 (unaudited) Assets Current assets: Cash and cash equivalents $ 6,805 $ 22,544 Available-for-sale investments 71,677 75,622 Other receivables 1,628 2,436 Prepaid expenses 10,187 2,390 Total current assets 90,297 102,992 Restricted cash 2,896 3,484 Property and equipment, net 5,184 5,531 Operating lease, right-of-use assets 5,942 6,727 Financing lease, right-of-use assets 1,490 1,788 Other assets 130 131 Total assets $ 105,939 $ 120,653 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 1,255 $ 3,529 Accrued expenses 9,409 11,559 Current portion of operating lease liability 656 831 Current portion of financing lease liability 517 497 Total current liabilities 11,837 16,416 Long-term operating lease liability, net of current portion 11,514 12,339 Long-term financing lease liability, net of current portion 1,164 1,428 Commitments and contingencies (Note 4) Stockholders' equity: Preferred stock, $ 0.001 par value per share; 5,000,000 undesignated authorized shares as of June 30, 2024 (unaudited) and December 31, 2023; no shares issued or outstanding as of June 30, 2024 (unaudited) and December 31, 2023 — — Common stock, $ 0.001 par value per share; 170,000,000 authorized shares as of June 30, 2024 (unaudited) and December 31, 2023; issued and outstanding shares – 75,796,198 as of June 30, 2024 (unaudited) and 63,286,404 as of December 31, 2023 76 63 Additional paid-in capital 581,520 558,692 Accumulated other comprehensive loss ( 168 ) ( 74 ) Accumulated deficit ( 499,820 ) ( 468,023 ) Total aTyr Pharma, Inc. stockholders' equity 81,608 90,658 Noncontrolling interest in Pangu BioPharma Limite

View Full Filing

View this 10-Q filing on SEC EDGAR